College of Psychiatric and Neurologic Pharmacists

Symposia Brochure

Click on the icon on the right to download the 2003 Industry Symposia Brochure. (Note: You will need Adobe Acrobat Reader to view this file.)

Thursday, May 1, 10:00 a.m.-12:30 p.m.

Sponsor: Ortho-McNeil Pharmaceutical
Title: Current Understanding of Eating Disorders and Weight Management
Program Location: The Francis Marion, Charleston, SC

Overview:
Eating disorders and obesity are increasing in prevalence in the United States, lending urgency to the development of new and more effective treatments. This luncheon symposium will review the current understanding of eating disorders and their management, with emphasis on binge eating disorder (BED) and bulimia nervosa. BED is identified as the most common eating disorder, affecting nearly one third of patients enrolled in weight-loss programs. There is no established ideal treatment, particularly when BED is associated with obesity. However, efficacy has been reported in clinical trials of selected antidepressants and anticonvulsants.

Other topics to be addressed include the prevalence of overweight and obesity, the associated morbidity, and the health benefits of even modest weight loss. A subject of particular importance is treatment-induced weight gain as an "iatrogenic" comorbidity of many disorders, especially psychiatric disorders. Prevalence of obesity in the drug-treated psychiatric population is two to five times higher than in the general population and substantially reduces compliance. Rational drug selection based on awareness of the potential impact on weight management will also be discussed.

Objectives:
Upon completion of this program, participants should be able to:

• Understand the classification, epidemiology, and risk factors of eating disorders, with emphasis on binge eating disorder and bulimia nervosa.
• Recognize the prevalence of binge-eating disorder and its association with obesity.
• Describe current approaches to the pharmacotherapy of eating disorders, specifically binge eating disorder and bulimia nervosa.
• Identify investigational drugs for the treatment of binge eating disorder and bulimia nervosa.
• Understand comorbid medical conditions associated with weight gain and obesity.
• Recognize the impact of weight gain as a side effect of certain drugs used in the treatment of medical and psychiatric disorders.

Faculty:

• Sally K. Guthrie, PharmD, BCPP
  College of Pharmacy
  University of Michigan
  Ann Arbor, MI
• Louis Aronne, MD
  Clinical Associate Professor of Medicine
  Weill Cornell Medical College
  New York, NY
• Scott Crow, MD
  Associate Professor of Psychiatry
  University of Minnesota
  Department of Psychiatry
  Minneapolis, MN

ACPE*: Rutgers University Ernest Mario School of Pharmacy is accredited by the American Council on Pharmaceutical Education as a provider of continuing pharmaceutical education. This program is approved for 2.0 contact hours of continuing pharmaceutical education credit (0.6 CEUs) for participants who submit a program evaluation at the conclusion of the presentation.
Program Number: #038-999-03-023-L04

Registration:
To register for this program online or by fax, go to:
http://www.educationalresource.com

Thursday, May 1, 6:30-9:30 p.m.

Sponsor: Pfizer
Title: A New Paradigm for Treatment over the Life Cycle of Schizophrenia: Acute Psychosis to Long-term Outcomes.
Program Location: The Francis Marion, Charleston, SC

Learning Objectives:
At the conclusion of the program, participants should be able to:

• Measure the efficacy and safety profiles of atypical and typical antipsychotics on the basis of their pharmacological profiles;
• Discuss critically the magnitude of metabolic changes associated with antipsychotic therapy, including weight gain, diabetes and hyperlipidemia;
• Identify treatment options to maximize the benefits of drug therapy across the spectrum of symptoms associated with schizophrenia.

Description:
The past decade has ushered in a new era of treatment options for people with schizophrenia. The new atypical antipsychotic agents offer many advantages over the older typical agents by improving negative symptom control while also maintaining control of positive symptoms. These advantages are tempered, however, by health concerns including weight gain, increased prevalence of hyperlipidemia, and diabetes.
Improved outcomes provided by the new treatment options are imperiled by the side effects of the very same treatment options. Side effects associated with these treatments often cause metabolic complications that increase patient morbidity and mortality. Recent advances in the development of atypical antipsychotics now offer clinicians new medication options that provide efficacy in relieving the positive and negative psychiatric symptoms of schizophrenia while maintaining a favorable safety and tolerability profile. As significant progress is made with improving the life span of people with schizophrenia, new attention must be given to managing the patient’s overall health. By carefully crafting a treatment plan encompassing both psychiatric and metabolic health, today’s clinicians can offer significant improvements in quality of life to people with schizophrenia.

Faculty

• Larry Ereshefsky, PharmD, FCCP, BCPP
  Professor, Pharmacy and Psychiatry
  University of Texas College of Pharmacy
  Austin, Texas
• Michael F. Green, PhD
  Professor, Department of Psychiatry and Biobehavior Sciences
  Geffen School of Medicine
  University of California at Los Angeles
  Los Angeles, California
• Robert L. Dufresne, Ph.D., Ph.D., BCPS, BCPP
  Associate Professor of Pharmacy
  University of Rhode Island College of Pharmacy
  Psychiatric Pharmacotherapy Specialist, Providence VA Medical Center
  Providence, Rhode Island

ACPE: The University of Texas College of Pharmacy is approved by the American Council on Pharmaceutical Education (ACPE) as a provider of continuing pharmaceutical education. This program is approved for 0.2 CEUs (2 contact hours) of continuing pharmaceutical education.
Program Number: 067-999-03-011-L01

Friday, May 2, 5:30-8:00 a.m. (Breakfast 5:30-6:00, Symposium 6:00-8:00)

Sponsor: Bristol-Myers Squibb Company/Otsuka America Pharmaceutical Inc.
Title: Antipsychotic Therapy in the 21st Century: Improving Clinical Outcomes
Brief Overview: During this breakfast session, the faculty will review the evolution of antipsychotics based on their mechanism of action and will also take a close look at their impact of efficacy and adverse effects on the effective management of psychotic disorders.
Program Location: The Francis Marion, Charleston, SC

Description: Psychotic disorders impose a tremendous burden on both patients and society with the costs of schizophrenia alone estimated at $65 Billion in the United States. An increased understanding of the underlying pathophysiology of psychosis has driven the ongoing evolution of pharmacotherapy. Although the atypical agents generally decreased extra-pyramidal symptoms (EPS) compared with conventional medications, EPS can remain a concern, particularly in special populations with heightened sensitivity such as geriatric and bipolar mania patients. The atypical agents also demonstrate a number of other troublesome adverse effects to different degrees with different agents. Of particular concern are metabolic adverse effects --weight gain, lipid abnormalities, glucose dysregulation, and diabetes-- that may decrease treatment adherence, increase cardiovascular risk, impair overall patient health and impose considerable burdens on the health care system. A novel atypical antipsychotic agent with a unique mechanism of action based on stabilizing the dopamine-serotonin system has demonstrated strong efficacy against the spectrum of psychotic symptoms and a more benign adverse-effect profile than previous agents. This symposium will review and compare the use of atypical antipsychotic agents in various psychotic disorders with an emphasis on the impact on patients’ total health and clinical outcomes.

Presentation Topics:

• A Mechanism Based Review of Antipsychotic Evolution and Efficacy
  • C. Lindsay DeVane, PharmD
• The Impact of Adverse Effects on Antipsychotic Outcomes and Overall Patient Health
  • Raymond Love, PharmD, BCPP, FASHP
• Effective Management of the Spectrum of Psychotic Disorders
  • Charles Nemeroff, MD, PhD

Learning Objectives:
After attending this symposium, participants should be able to...

• Identify challenges and opportunities in the management of psychotic disorders
• Discuss novel antipsychotic mechanisms of action and the implications for efficacy, safety and tolerability
• Describe the role of antipsychotic therapy in schizophrenia, bipolar mania and special populations
• Compare the efficacy and adverse effect profiles of various atypical agents
• Describe the potential influence of antipsychotic adverse effects on patient total health and antipsychotic outcomes

Faculty:

• C. Lindsay DeVane, PharmD; Medical University of South Carolina (Chair)
• Charles Nemeroff, MD, PhD; Emory University
• Raymond Love, PharmD, BCPP, FASHP; University of Maryland, Baltimore

ACPE: The Health Science Center for Continuing Medical Education is accredited by the American Council on Pharmaceutical Education as a provider of continuing pharmaceutical education. This program has been approved for 2.0 contact hours or 0.2 CEUs. This educational activity is provided free of charge to participating pharmacists. In order to receive credit, participants must attend the program and complete the evaluation form and statement of credit request form. No partial credit will be awarded. Statements of continuing parmaceutical credits will be mailed within 4 to 6 weeks of the program.
Program Number: 247-000-03-006-L01

Saturday, May 3, 6:00-8:00 a.m.

Sponsor: AstraZeneca Pharmaceuticals LP
Title: A Dose of the Blues: Issues Involved in Dosing the Atypical Antipsychotics
Brief Overview: ACPE-accredited Educational Poster Session and Buffet Breakfast
Participants will view educational posters while discussing issues with expert faculty. Upon completion of a posttest, participants will be awarded 1 hour of ACPE credit. This credit hour may be completed at any time during the hours of 6:00-8:00 AM.
Program Location: The Francis Marion, Charleston, SC
Target Audience: Pharmacists and other health care providers involved in dosing atypical antipsychotics.

Learning Objectives:

• Identify pharmacokinetic variables that are important dosing considerations for the atypical antipsychotics.
• Review historical and new pharmacologic properties of the atypical antipsychotics that will help optimize selection and dosing of this drug class.
• Outline clinical considerations for successful switching between antipsychotic agents.
• Describe the advantages and appropriate use of several switching strategies.
• Briefly review dosing in special clinical situations.
• Describe the different dosage formulations of currently available antipsychotic agents.
• Identify primary clinical use for novel dosage forms for antipsychotic agents.
• Describe the clinical evidence for the therapeutic use of atypical antipsychotics in children and adolescents.
• Identify appropriate initial dosing regimens as well as evidence-based dose titrations suitable for elderly patients.

Faculty:

• Roger Sommi, PharmD, BCPP (Program Chair)
  Associate Professor, Pharmacy & Psychiatry
  University of Missouri-Kansas City
  Kansas City, Missouri
• John J. Spollen, III, MD
  Assistant Professor
  University of Arkansas for Medical Sciences
  Department of Psychiatry
  Little Rock, Arkansas
• Julie Dopheide, PharmD, BCPP
  Associate Professor of Clinical Pharmacy,
  Psychiatry and the Behavioral Sciences
  University of Southern California
  Schools of Pharmacy and Medicine
  Los Angeles, California
• Melody Ryan, PharmD, BCPS, CGP
  Assistant Professor
  University of Kentucky
  Colleges of Pharmacy and Medicine
  Lexington, Kentucky

ACPE: Creative Educational Concepts, Inc. is accredited by the American Council on Pharmaceutical Education as a provider of continuing pharmaceutical education. This program is acceptable for 1.0 contact hour (0.1 CEU). Statement of credit will indicate hours and CEUs based on participation. CEC complies with the Criteria for Quality for continuing education programming. Statement of credit will be issued to those participants completing a CE request form/posttest and will be mailed within 10 business days.
Program Number: 245-000-02-056-L01

Saturday, May 3, 6:45-10:00 p.m.

Sponsor: Janssen Pharmaceutica, Inc.
Title: Unmet Needs in the Treatment of Mood Disorders: Role of Atypical Antipsychotics
Brief Overview: This dinner program will discuss the unmet needs in the treatment of mood disorders and current pharmacological approaches, including the role of atypical antipsychotics, to improve outcomes.
Program Location: The Francis Marion, Charleston, SC

Learning Objectives:
At the completion of this program attendees should be able to:

• Identify unmet needs in the treatment of mood disorders
• Compare rates of treatment response, remission, and refractoriness of various mood disorders with established pharmacotherapies
• Describe the rationale for using atypical antipsychotics as monotherapy and adjunctive therapy in treatment of mood disorders based on their mechanism of action
• Discuss efficacy of atypical antipsychotics in treatment of mood disorders, based on recent research in the areas of bipolar mania and depression, major depression and treatment-resistant depression
• Summarize the most recent treatment guidelines for mood disorders and make specific treatment recommendations based on the efficacy and safety of available medications alone and in combination

Faculty:

• Program Chair:
  John Markowitz, PharmDM
  Associate Professor of Pharmaceutical Sciences
  Medical University of South Carolina
  Charleston, South Carolina
• José A. Rey, PharmD, BCPP
  Nova Southeastern University
• Gary M. Levin, Pharm.D., BCPP, FCCP
  South University School of Pharmacy
• M. Lynn Crismon, PharmD
  University of Texas, College of Pharmacy

Schedule:

ACPE: Medical Education Resources (MER) is approved by the American Council of Pharmaceutical Education as a provider of continuing pharmaceutical education. This program is approved for 2.5 contact hours (0.25 CEUs) in states that recognize ACPE.
Program Number: 816-000-03-001-L04.